Company intelligence / Profile preview
Neuronyx, Inc.
Malvern, Pennsylvania, United Statesneuronyx.site ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Neuronyx developed stem cell-based therapies using adult bone marrow-derived cells to repair damaged heart tissue after myocardial infarction and later targeted surgical wound healing. Despite promising early results and significant venture funding ($55M+), the company discontinued its programs after rebranding as Garnet BioTherapeutics due to inability to sustain operations.[5][8]
- Therapeutic areas
- OncologyCardiovascularNeurology
- Modalities
- Cellular therapiesStem cell therapy (specifically adult bone marrow-derived stem cells)[3][5]
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
No major pharmaceutical or biotech partnerships publicly documented.
Beyond the preview
Go deeper on Neuronyx, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neuronyx, Inc..